Alzheimer’s drug trial seeks answers among genetically predisposed population

Although genetics has been linked to only one form of early-onset Alzheimer’s diseaseand accounts for only a small percentage of patients overall, researchers will soon begin a five-year clinical trial among this population, reports the New York Times. Three hundred members of a large family living in and around Medellín, Colombia are known to have a genetic mutation that results in declines in cognitive impairment beginning around age 45.   

Part of the federal government’s national agendato prevent and treat Alzheimer’s disease, the clinical trial will administer a drug to people who do not yet show signs of impairment. The study is planned to last five years at a cost of $100 million, but some researchers are hopeful that sophisticated tests will indicate whether or not the drug has efficacy in as little as two years.

I Advance Senior Care

I Advance Senior Care is the industry-leading source for practical, in-depth, business-building, and resident care information for owners, executives, administrators, and directors of nursing at assisted living communities, skilled nursing facilities, post-acute facilities, and continuing care retirement communities. The I Advance Senior Care editorial team and industry experts provide market analysis, strategic direction, policy commentary, clinical best-practices, business management, and technology breakthroughs.

I Advance Senior Care is part of the Institute for the Advancement of Senior Care and published by Plain-English Health Care.